| FSAP Protects against Histone-Mediated Increase in Endothelial Permeability In Vitro. | FSAP Protects against Histone-Mediated Increase in Endothelial Permeability In Vitro.
Cui XY, Stavik B, Thiede B, Sandset PM, Kanse SM., Free PMC Article | 01/7/2023 |
| Development of a Factor VII Activating Protease (FSAP) generation assay and its application in studying FSAP in venous thrombosis. | Development of a Factor VII Activating Protease (FSAP) generation assay and its application in studying FSAP in venous thrombosis.
Etscheid M, Hanschmann KM, Sandset PM, Kanse SM. | 12/3/2022 |
| FSAP aggravated endothelial dysfunction and neurological deficits in acute ischemic stroke due to large vessel occlusion. | FSAP aggravated endothelial dysfunction and neurological deficits in acute ischemic stroke due to large vessel occlusion.
Tian DS, Qin C, Zhou LQ, Yang S, Chen M, Xiao J, Shang K, Bosco DB, Wu LJ, Wang W., Free PMC Article | 03/26/2022 |
| Factor VII activating protease (FSAP) is not essential in the pathophysiology of angioedema in patients with C1 inhibitor deficiency. | Factor VII activating protease (FSAP) is not essential in the pathophysiology of angioedema in patients with C1 inhibitor deficiency.
Gramstad OR, Kandanur SPS, Etscheid M, Nielsen EW, Kanse SM. | 02/26/2022 |
| Association between FSAP 1601G>A polymorphism and venous thromboembolism risk: A meta-analysis. | Association between FSAP 1601G>A polymorphism and venous thromboembolism risk: A meta-analysis.
Da L, Jiahui Z, Xiaoqiang L. | 06/26/2021 |
| Cellular effects of factor VII activating protease (FSAP). | Cellular effects of factor VII activating protease (FSAP).
Byskov K, Etscheid M, Kanse SM. | 06/26/2021 |
| Characterization of the enzymatic activity of the serine protease domain of Factor VII activating protease (FSAP). | Characterization of the enzymatic activity of the serine protease domain of Factor VII activating protease (FSAP).
Nielsen NV, Roedel E, Manna D, Etscheid M, Morth JP, Kanse SM., Free PMC Article | 11/21/2020 |
| PAR-1 and -2 mediate cellular effects of factor VII activating protease (FSAP) | Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP).
Byskov K, Le Gall SM, Thiede B, Camerer E, Kanse SM. | 07/25/2020 |
| FSAP inhibited VEGF165-mediated angiogenesis. | VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization.
Uslu Ö, Herold J, Kanse SM., Free PMC Article | 07/11/2020 |
| HABP2 Marburg-I variant is a strong regulator of FSAP activity. A novel locus near ADCY2 was identified as a potential additional regulator of FSAP activity. | Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity.
Olsson M, Stanne TM, Pedersen A, Lorentzen E, Kara E, Martinez-Palacian A, Rønnow Sand NP, Jacobsen AF, Sandset PM, Sidelmann JJ, Engström G, Melander O, Kanse SM, Jern C., Free PMC Article | 12/28/2019 |
| The G534E variant might be considered a rare polymorphism of HABP2 not associated with increased risk of familial non-medullary thyroid cancer in Brazilian kindreds. | The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds.
de Mello LEB, Araujo AN, Alves CX, de Paiva FJP, Brandão-Neto J, Cerutti JM. | 06/22/2019 |
| Altering fibrin clot properties by fibrinogenolysis is a novel function of FSAP in the vasculature, which facilitates clot lysis and may in vivo contribute to reduced fibrin deposition during thrombosis. | Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP).
Etscheid M, Subramaniam S, Lochnit G, Zabczyk M, Undas A, Lang IM, Hanschmann KM, Kanse SM. | 05/25/2019 |
| three novel MD loci were identified (at P < 5 x 10(- 8)): one for percent dense volume (HABP2) and two for the absolute dense volume (INHBB, LINC01483). INHBB is an established locus for ER-negative breast cancer, and HABP2 and LINC01483 represent putative new breast cancer susceptibility loci | Common genetic variation and novel loci associated with volumetric mammographic density.
Brand JS, Humphreys K, Li J, Karlsson R, Hall P, Czene K., Free PMC Article | 03/23/2019 |
| The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of familial nonmedullary thyroid carcinoma. | Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
de Randamie R, Martos-Moreno GÁ, Lumbreras C, Chueca M, Donnay S, Luque M, Regojo RM, Mendiola M, Hardisson D, Argente J, Moreno JC. | 11/10/2018 |
| The MI-SNP and MII-SNP FSAP gene polymorphisms were not predictive or prognostic biomarkers for coronary artery diseaseor its main risk factors. | Expression of the Marburg I Single Nucleotide Polymorphism (MI-SNP) and the Marburg II Single Nucleotide Polymorphism (MII-SNP) of the Factor VII-Activating Protease (FSAP) Gene and Risk of Coronary Artery Disease (CAD): A Pilot Study in a Single Population.
Parahuleva MS, Schieffer B, Klassen M, Worsch M, Parviz B, Hölschermann H., Free PMC Article | 10/20/2018 |
| NETs bind to FSAP, but do not activate pro-FSAP unless histones are released from NETs by DNAse. This activation of FSAP is likely to be important in diminishing the cytotoxic effect of histones, thus limiting the damaging effect of NETosis. | Interaction of factor VII activating protease (FSAP) with neutrophil extracellular traps (NETs).
Grasso S, Neumann A, Lang IM, Etscheid M, von Köckritz-Blickwede M, Kanse SM. | 08/18/2018 |
| Regulation of gene expression by FSAP in vascular smooth muscle/endothelial cells accounts for its vasculo-regulatory properties. | Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells.
Byskov K, Boettger T, Ruehle PF, Nielsen NV, Etscheid M, Kanse SM. | 06/9/2018 |
| The extent of CAC in women is positively associated with total FSAP, but negatively associated with the specific activity of FSAP suggesting that FSAP may play a role in the evolution of CVD in women. | Factor VII-activating protease: sex-related association with coronary artery calcification.
Ramanathan R, Gram JB, Sand NPR, Nørgaard BL, Diederichsen ACP, Vitzthum F, Schwarz H, Sidelmann JJ. | 06/2/2018 |
| Report peptide substrates used in determining substrate specificity of Factor VII activating protease. | Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Kara E, Manna D, Løset GÅ, Schneider EL, Craik CS, Kanse S. | 05/26/2018 |
| Two of 20 probands from families with history of PTC and breast carcinoma (BC) were evaluated by whole exome sequencing (WES) revealing HABP2 p.G534E. | HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Pinheiro M, Drigo SA, Tonhosolo R, Andrade SCS, Marchi FA, Jurisica I, Kowalski LP, Achatz MI, Rogatto SR., Free PMC Article | 04/28/2018 |
| No significant association was found between rs11196288 and early-onset ischemic stroke, large artery atherosclerotic stroke, or small vessel disease stroke. rs11196288 presented significant effect on late-onset SVD stroke susceptibility in the older population. | Association of GWAS-Reported Variant rs11196288 near HABP2 with Ischemic Stroke in Chinese Han Population.
Li SH, Shi CH, Li YS, Li F, Tang MB, Liu XJ, Zhang S, Wang ZL, Song B, Xu YM. | 03/31/2018 |
| study on a wide series of familial non-medullary thyroid cancers indicates that the HABP2(G534E) variant is frequent, but does not segregate with the disease | Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
Colombo C, Muzza M, Proverbio MC, Ercoli G, Perrino M, Cirello V, Vicentini L, Ferrero S, Fugazzola L. | 03/10/2018 |
| Letter: G534E variant in HABP2 is not associated with non-medullary thyroid cancer in the Spanish population. | G534E Variant in HABP2 and Nonmedullary Thyroid Cancer.
Ruiz-Ferrer M, Fernández RM, Navarro E, Antiñolo G, Borrego S., Free PMC Article | 02/24/2018 |
| mutations were not found in familial non-medullary thyroid cancer, and the G534E variant is not the underlying genetic defect in a large sample of sporadic non-medullary thyroid cancer from the Middle East. | HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS, Murugan AK, Qasem E, Al-Hindi H. | 02/17/2018 |
| Study showed that lower FSAP antigen plasma levels were associated with a higher chance of arterial recanalization after tissue plasminogen activator treatment, suggesting an involvement of FSAP in tissue plasminogen activator-induced clot lysis. FSAP antigen determination might be useful in predicting tissue plasminogen activator response in stroke patients. | Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke.
Bustamante A, Díaz-Fernández B, Giralt D, Boned S, Pagola J, Molina CA, García-Berrocoso T, Kanse SM, Montaner J. | 10/7/2017 |